Interní Med. 2012; 14(10): 357-360

New possibilities of prevention and therapy of cardiovascular embolism

MUDr.Zdeněk Coufal
Kardiovaskulární centrum, Interní klinika IPVZ, Krajská nemocnice T. Bati, a. s., Zlín

Heparin, first antikoagulant agent, will celebrate 100-year anniversary from its discovery. Warfarin is clinically used during past 60 years.

Patients with atrial fibrillation are under risk of stroke and CVE. New ESC guidelines for the management of atrial fibrillation stratifies

risk of stroke and CVE and quantifies bleeding risk in optimal contolled treatment by OAC. Based on results from recent studies RE-LY,

ROCKET AF and AVERROES new and safer direct oral antiocagulants dabigatran and rivaroxaban are introduced on the market. New

antikoagulant agents are shown to be more potent in prevention of stroke ant CVE simultaneously with lower bleeding risk.

Keywords: atrial fibrillation, warfarin, dabigatran, rivaroxaban, apixaban, stroke, cardiovascular embolism

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Coufal Z. New possibilities of prevention and therapy of cardiovascular embolism. Interní Med. 2012;14(10):357-360.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Walenga JM, Fareed J, Jeske WP, Frapaise FX, Bick RL, Samama MM. Development of a Synthetic Heparin Pentasaccharide: Fondaparinux. Turk J Haematol. 2002; 19, Sv. 2: 137-150. Go to original source...
    2. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant. Circulation. 2002; 106: 2550-2554. Go to original source... Go to PubMed...
    3. Connolly SJ, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    4. https://www.dcri.org/news-publications/slides-presentations/ROCKET-AF-LBCT-FINAL.ppt/view?searchterm=rocket. [Online]
    5. http://www.escardio.org/about/press/press-releases/esc10-stockholm/Pages/AVERROES-trial.aspx. [Online]
    6. http://www.nejm.org/doi/full/10.1056/NEJMoa1107039.[Online]
    7. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010; 31, Sv. 19: 2369-2429..
    8. Van Ryn J, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin. Thromb Haemost 2010; 103: 1116-1127. Go to original source... Go to PubMed...
    9. SPC Pradaxa 110 mg. 150 mg tvrdé tobolky, 04/2012.
    10. Huisman MV, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thrombosis and Haemostasis 2012; 107, 5: 838-847. Go to original source... Go to PubMed...
    11. SPC Pradaxa 04/2012.
    12. Coleman CI, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012; 28(5): 669-680. Go to original source... Go to PubMed...
    13. Mueck W, et al. Rivaroxaban - Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention. Clin Pharmacokinet. 2011; 50(10): 675-686. Go to original source... Go to PubMed...
    14. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight-heparin. Thromb Haemost. 2008: 807-818. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.